4.0 Review

Disease-modifying therapies and symptomatic management for primary biliary cholangitis

期刊

出版社

MA HEALTHCARE LTD
DOI: 10.12968/hmed.2021.0247

关键词

Cirrhosis; Obeticholic acid; Primary biliary cholangitis; Primary biliary cirrhosis; Ursodeoxycholic acid

向作者/读者索取更多资源

Primary biliary cholangitis is characterized by autoimmune destruction of bile ducts, with gaps in patient care highlighted in publications. Ursodeoxycholic acid is recommended for all patients, with potential disease-modifying therapies like fibrates and budesonide requiring further investigation. Emerging therapies show initial promise but more randomized trials are needed for evaluation.
Primary biliary cholangitis is a chronic condition characterised by autoimmune destruction of intralobular bile ducts. Publications have shown widespread gaps in the care of patients with primary biliary cholangitis. This article reviews the literature regarding currently licensed first- and second-line therapies and evaluates therapeutic options for symptomatic management of primary biliary cholangitis. Ursodeoxycholic acid is recommended for all patients with primary biliary cholangitis, with obeticholic acid available as second-line therapy, both having demonstrated safety and efficacy. Potential disease-modifying therapies, such as fibrates and budesonide, require further investigation before licensing. Cholestyramine is first-line therapy for pruritus, albeit with limited evidence and common side-effects. There is no licensed therapy for primary biliary cholangitis-related fatigue; treating underlying causes where applicable is recommended. Disease-modifying and symptomatic therapies must be considered in tandem when managing patients with primary biliary cholangitis. Emerging therapies show initial promise but further randomised trials with long-term follow up are required to evaluate their efficacy as single or combination therapies.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.0
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据